Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors

Aardvark Therapeutics, Inc. (AARD) announced an update on their ongoing clinical study.

The Hunger Elimination or Reduction Objective (HERO) open-label extension is a Phase 3 study testing Aardvark Therapeutics’ ARD-101 in people with Prader-Willi syndrome. It aims to see if long-term treatment can safely reduce extreme hunger and improve daily behavior, a key unmet need for this rare and hard-to-treat condition.

ARD-101 is an oral drug given twice a day over about a year. The goal is to curb constant hunger and related behavior in Prader-Willi patients, which could also reduce caregiver burden and long-term health risks if results are positive.

The trial uses a single treatment group, so every enrolled patient receives ARD-101 rather than being randomized to placebo. It is open-label, meaning both doctors and patients know they are getting the drug, and the main focus is to assess safety and benefit in real-world style use.

This is an interventional treatment study, not an observational one, and is designed to extend prior Phase 3 exposure from the AVK-101-301 trial. The key outcome is change in a standard hunger behavior score, supported by tracking side effects and daily diary data from patients and caregivers.

The study was first submitted on September 21, 2025, indicating when the sponsor formally moved this long-term plan into the regulatory system. The most recent update was filed March 17, 2026, which is important because it shows the sponsor is still actively managing the record and the development path.

The current trial status is listed as suspended, which signals a pause rather than a full termination. For investors, this usually means timelines are in flux, and it may reflect safety signals, design changes, or strategic reprioritization that will need clarification before confidence returns.

For Aardvark Therapeutics (AARD), the pause in this Phase 3 extension raises near-term risk around the ARD-101 program and can weigh on valuation, especially if the drug is a central pipeline asset. Rare disease peers in obesity and appetite control have drawn strong interest, so any delay here may shift risk-on capital toward better-de‑risked players.

Competitors in obesity and genetic metabolic diseases, including larger firms with late-stage weight-loss drugs, may look relatively safer while ARD-101’s path is uncertain. Still, if the suspension is resolved with a clear plan and supportive data from the core Phase 3 trial, sentiment could recover quickly in a space where positive catalysts are rewarded.

The HERO open-label extension for ARD-101 in Prader-Willi syndrome is currently suspended but remains an active listing, with details and updates available on the ClinicalTrials portal.

To learn more about AARD’s potential, visit the Aardvark Therapeutics, Inc. drug pipeline page.